The clinical trial results, which found that giving a person one-fifth of the standard yellow fever vaccine dose is effective and safe, will make it easier for governments and international organisations to prevent people from getting sick from yellow fever during outbreaks in times of vaccine shortage.
“When big yellow fever epidemics hit, countries and MSF need to access vaccines urgently,” said Dr Myriam Henkens, MSF international medical coordinator. “Vaccination is the most important measure for preventing the disease.”
“This study observes that treatment providers can now rest assured that giving people smaller doses of any of the World Health Organization (WHO)-prequalified yellow fever vaccines will protect the person in front of them, while helping to keep even more people safe,” she said.
The Epicentre study, in collaboration with the Kenya Medical Research Institute, the Senegalese branch of the French outfit, namely Institut Pasteur de Dakar, and the World Health Organisation (WHO), was a randomized, double-blind trial in Mbarara, Uganda and Kilifi, Kenya, conducted between 6 November 2017 and 21 February 2018.
During this period, researchers administered either one-fifth or a standard dose of yellow fever vaccine to 960 adults between the ages of 18 and 59, it said.
People receiving one-fifth of the dose were found to have an immunological response that was considered non-inferior to the standard dose. “This is an important step toward a future updated policy on fractional doses. Thanks to these results, the current WHO policy on fractional doses of yellow fever vaccines in times of shortages during an outbreak can be expanded to all prequalified vaccines,” it stated.
The clinical trial marks the first time that all four WHO prequalified yellow fever vaccines have been assessed in the same study. It used the only four existing WHO-approved vaccines, derived from multiple strains of the virus: 17DD (Bio-Manguinhos/Fiocruz, Brazil), 17D-213 (Federal State Unitary Enterprise of Chumakov Institut of Poliomyelitis and Viral Encephalitides, Russia), 17D-204 (Institut Pasteur de Dakar, Senegal), and 17D-204 (Sanofi Pasteur, France).
“This research is significant because it shows that trials involving different manufacturers, where their products are independently evaluated, is possible,” said Rebecca Grais, research director at Epicentre. “This is proof that global medical researchers can band together to do independent and objective research that results in products and recommendations that truly meet the needs of people, and ensure effective and safe medicines and vaccines,” she declared.
Yellow fever is a mosquito-borne acute viral haemorrhagic fever that causes 30,000 deaths per year, most of which occur in sub-Saharan Africa. However, the disease is on the rise in Central and South America. While this infection is asymptomatic or causes only mild symptoms in many people, a small percentage of those infected experience a more toxic stage of the disease that can cause internal bleeding and severe damage to the liver and kidneys. Approximately half the people who enter this stage of yellow fever die within a few days.
There’s no cure for yellow fever, so prevention is extremely important. A single dose of the vaccine can protect a person for life. Unfortunately, because it takes about 12 months to produce and it is difficult to forecast the quantities that will be needed each year to respond to outbreaks, there are often shortages of the vaccine. This means that production capacity cannot meet global needs during epidemics, leaving people without protection and medical providers like MSF and governments empty-handed when vaccines are needed most.
Yellow fever is endemic to 34 countries in Africa. Since 2000, MSF teams have responded to yellow fever epidemics in Angola, Democratic Republic of Congo (DRC) - including in 2015-16 during DRC's largest outbreak in 30 years - Guinea, Sudan, Sierra Leone, Central African Republic and Chad, among others. Read More...epaper.ippmedia.com